AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29097640 — intervention group
Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 270
Study 25971920 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Number of subjects: 179
Study 25971920 — intervention group
Group type: COMPARATOR
Intervention: No extraction
Number of subjects: 179
Study 24224515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal DEX 1 μg·kg(‐1) (group D1)
Number of subjects: 40
Study 24224515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal DEX 2 μg·kg(‐1) (group D2)
Number of subjects: 40
Study 22128226 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (combined low-, medium-, high-dose)
Number of subjects: 235
Study 22128226 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose sildenafil
Number of subjects: 235
Study 22128226 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sildenafil
Number of subjects: 235
Study 22128226 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sildenafil
Number of subjects: 235
Study 22128226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 19243716 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose varenicline (1 mg BID)
Number of subjects: 72
Study 19243716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose varenicline (0.5 mg BID)
Number of subjects: 72
Study 19243716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose varenicline (0.5 mg once daily)
Number of subjects: 72
Study 19243716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for high-body-weight group)
Number of subjects: 72
Study 19243716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for low-body-weight group)
Number of subjects: 72
Study 19243716 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose varenicline (for low-body-weight group)
Number of subjects: 72
Study 19243716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose varenicline (for low-body-weight group)
Number of subjects: 72
Study 17559730 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% film-forming solution (FFS)
Number of subjects: 0
Study 17559730 — intervention group
Group type: COMPARATOR
Intervention: Terbinafine 1% cream (Lamisil)
Number of subjects: 0
Study 17559730 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing at 30 min
Number of subjects: 0
Study 17559730 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing at 12 h
Number of subjects: 0
Study 15008648 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-dependent processing style induced in Experiment 2
Number of subjects: 0
Study 15008648 — intervention group
Group type: COMPARATOR
Intervention: Behavioral mimicry by experimenter in Experiment 3
Number of subjects: 0
Study 11800303 — intervention group
Group type: COMPARATOR
Intervention: Quinine sulfate 10 mg/kg/day for at least 7 days (group I)
Number of subjects: 60
Study 11800303 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate 2 mg/kg as the first dose, 1 mg/kg every 12 hours orally for at least 5 days together with split doses of mefloquine, 15 mg/kg and 6 hours later 10 mg/kg orally 1 day after artesunate was stopped (group II)
Number of subjects: 60
Study 11800303 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 60
Study 9192123 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (25-100 mg)
Number of subjects: 42
Study 9192123 — intervention group
Group type: COMPARATOR
Intervention: Control (no drugs)
Number of subjects: 42
Study 1327634 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alanine infusion (0.70, 1.40, or 2.80 nmol/kg body weight over 4.5 min)
Number of subjects: 6
Study 1327634 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alanine infusion (11.2 mmol/kg body weight in male Wistar rats)
Number of subjects: 6
Study 2947712 — intervention group
Group type: EXPERIMENTAL
Intervention: Yukuiling
Number of subjects: 250
Study 2947712 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 250
Study 2947712 — intervention group
Group type: COMPARATOR
Intervention: Weidening
Number of subjects: 250
Study 31293098 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 10 min of Finnish sauna bathing (80.2 ± 3.2°C, 23 ± 2% humidity)
Number of subjects: 21
Study 31293098 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 10 min of sauna bathing separated by 10 min of rest outside the sauna
Number of subjects: 21
Study 31293098 — intervention group
Group type: COMPARATOR
Intervention: Time control period (10 min of seated rest outside the sauna)
Number of subjects: 21
Study 29633373 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg at baseline, Weeks 1, 2, 3, and 4, and every 4 weeks thereafter until Week 52
Number of subjects: 160
Study 29633373 — intervention group
Group type: COMPARATOR
Intervention: Narrow-band ultraviolet B (nb-UVB) phototherapy, one/two cycles for 12 weeks each (maximum 28-week break between cycles)
Number of subjects: 160
Study 26549475 — intervention group
Group type: EXPERIMENTAL
Intervention: High increasing trajectory group (11.6%)
Number of subjects: 1216
Study 26549475 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high trajectory group (1.9%)
Number of subjects: 1216
Study 26549475 — intervention group
Group type: COMPARATOR
Intervention: Consistently low trajectory group (51.1%)
Number of subjects: 1216
Study 26549475 — intervention group
Group type: COMPARATOR
Intervention: Consistently moderate trajectory group (29.8%)
Number of subjects: 1216
Study 26549475 — intervention group
Group type: EXPERIMENTAL
Intervention: High declining trajectory group (5.5%)
Number of subjects: 1216
Study 24449005 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatially congruent sound condition
Number of subjects: 0
Study 24449005 — intervention group
Group type: COMPARATOR
Intervention: Spatially incongruent sound condition
Number of subjects: 0
Study 23095370 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 78
Study 23095370 — intervention group
Group type: COMPARATOR
Intervention: Continuous venovenous hemodialysis (CVVHD)
Number of subjects: 78
Study 23095370 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH
Number of subjects: 78
Study 23095370 — intervention group
Group type: COMPARATOR
Intervention: CVVHD
Number of subjects: 78
Study 19910621 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia
Number of subjects: 2463
Study 19910621 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS values <40 for >5 min
Number of subjects: 2463
Study 17638700 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (7-day course)
Number of subjects: 296
Study 17638700 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (3-day course)
Number of subjects: 296
Study 17638700 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline and Azithromycin
Number of subjects: 296
Study 16164829 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (AT)
Number of subjects: 0
Study 16164829 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study 11918500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous corticosteroids
Number of subjects: 53
Study 11918500 — intervention group
Group type: COMPARATOR
Intervention: Oral corticosteroids
Number of subjects: 53
Study 9805221 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic visual analogue scale (Apple Newton Message Pad)
Number of subjects: 12
Study 9805221 — intervention group
Group type: COMPARATOR
Intervention: Paper visual analogue scale questionnaire
Number of subjects: 12
Study 9805221 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference assessment after both methods
Number of subjects: 12
Study 7631609 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (n = 32)
Number of subjects: 55
Study 7631609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 23)
Number of subjects: 55
Study 7631609 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin and Placebo
Number of subjects: 55
Study 2280168 — intervention group
Group type: EXPERIMENTAL
Intervention: Irlen filter treatment group (n = 11)
Number of subjects: 30
Study 2280168 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision therapy treatment group (n = 11)
Number of subjects: 30
Study 2280168 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 30
Study 6107987 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (600 pg/ml) added to distending fluid during 3 test periods in 10 subjects
Number of subjects: 20
Study 6107987 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to distending fluid during 3 test periods in 10 control subjects
Number of subjects: 20
Study 31008641 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy Challenge Alcohol Literacy Curriculum (ECALC)
Number of subjects: 121
Study 31008641 — intervention group
Group type: COMPARATOR
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 121
Study 31464617 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuzi Yanzong pill
Number of subjects: 0
Study 31464617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28859942 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement educational intervention
Number of subjects: 2281
Study 28859942 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2281
Study 26449227 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (final dose 0.07 mg/kg)
Number of subjects: 0
Study 26449227 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (final dose 1.11 μg/kg)
Number of subjects: 0
Study 26449227 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (final dose 0.084 mg/kg)
Number of subjects: 0
Study 26449227 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (placebo)
Number of subjects: 0
Study 23584193 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 772
Study 23584193 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 772
Study 21540865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide (500, 1000 and 2000 mg) combined with cetuximab, cisplatin and 5-fluorouracil
Number of subjects: 10
Study 19718255 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopathic care (NC)
Number of subjects: 81
Study 19718255 — intervention group
Group type: COMPARATOR
Intervention: Standardized psychotherapy intervention (PT)
Number of subjects: 81
Study 17875819 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (20 mg)
Number of subjects: 10
Study 17875819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15468362 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline + Rifampin (D/R)
Number of subjects: 30
Study 15468362 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (D)
Number of subjects: 30
Study 11583883 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and six-month angiographic follow-up
Number of subjects: 1058
Study 11583883 — intervention group
Group type: COMPARATOR
Intervention: Clinical follow-up alone
Number of subjects: 1058
Study 11301566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular progestin therapy (medroxyprogesterone acetate)
Number of subjects: 12
Study 11301566 — intervention group
Group type: COMPARATOR
Intervention: Oral progestin therapy (medroxyprogesterone acetate)
Number of subjects: 12
Study 8165049 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride supplement (0.013 mmol or 0.25 mg)
Number of subjects: 17
Study 8165049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control study)
Number of subjects: 17
Study 3043945 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromid (Ultravist)
Number of subjects: 46
Study 3043945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioglicinate (Rayvist)
Number of subjects: 46
Study 3043945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglinate (Hexabrix)
Number of subjects: 46
Study 31826241 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin
Number of subjects: 549
Study 31826241 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 549
Study 31826241 — intervention group
Group type: EXPERIMENTAL
Intervention: ELN favorable‐risk group
Number of subjects: 549
Study 31826241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower WBC counts
Number of subjects: 549
Study 31248458 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-targeted kinase inhibitors after immune checkpoint inhibitors
Number of subjects: 6
Study 31248458 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy following immune checkpoint inhibitors
Number of subjects: 6
Study 28379519 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of GLP-1, OXM, and PYY (GOP) at doses of 4 pmol/kg/min for GLP-1 and OXM, and 0.4 pmol/kg/min for PYY
Number of subjects: 0
Study 28379519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26659941 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% plus Betamethasone Dipropionate 0.064% aerosol foam
Number of subjects: 426
Study 26659941 — intervention group
Group type: COMPARATOR
Intervention: Vehicle aerosol foam
Number of subjects: 426
Study 23036625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 20
Study 23036625 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20
Study 20059594 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide and oxygen (Method A)
Number of subjects: 30
Study 20059594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide, sevoflurane, and oxygen (Method B)
Number of subjects: 30
Study 17899135 — intervention group
Group type: COMPARATOR
Intervention: Extraction drilling
Number of subjects: 26
Study 17899135 — intervention group
Group type: EXPERIMENTAL
Intervention: Compaction drilling
Number of subjects: 26
Study 15947624 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing fluid intake in IDO group
Number of subjects: 110
Study 15947624 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing fluid intake in USI group
Number of subjects: 110
Study 15947624 — intervention group
Group type: COMPARATOR
Intervention: Caffeine restriction (changing from caffeine containing to decaffeinated drinks)
Number of subjects: 110
Study 12838298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (ciprofloxacin 750 mg 12 hourly + amoxicillin-clavulanate 675 mg 8 hourly for 5 days)
Number of subjects: 102
Study 12838298 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics (gentamicin and tazocin until hospital discharge)
Number of subjects: 102
Study 12838298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics
Number of subjects: 102
Study 12838298 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 102
Study 10809399 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond XT (n = 8)
Number of subjects: 16
Study 10809399 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II (n = 8)
Number of subjects: 16
Study 10809399 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT with liquid resin (n = 8)
Number of subjects: 16
Study 10809399 — intervention group
Group type: COMPARATOR
Intervention: Phase II with liquid resin (n = 8)
Number of subjects: 16
Study 8877673 — intervention group
Group type: EXPERIMENTAL
Intervention: moexipril 7.5 mg/day (in addition to hydrochlorothiazide 25 mg/day)
Number of subjects: 108
Study 8877673 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil SR 180 mg/day (in addition to hydrochlorothiazide 25 mg/day)
Number of subjects: 108
Study 8877673 — intervention group
Group type: EXPERIMENTAL
Intervention: moexipril 15 mg/day (after dose increase for patients with SDBP of > or = 90 mmHg)
Number of subjects: 108
Study 8877673 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil SR 240 mg/day (after dose increase for patients with SDBP of > or = 90 mmHg)
Number of subjects: 108
Study 8877673 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of moexipril or verapamil SR with low-dose hydrochlorothiazide
Number of subjects: 108
Study 1815115 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% methohexital solution
Number of subjects: 0
Study 1815115 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg methohexital
Number of subjects: 0
Study 1815115 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration of residual methohexital
Number of subjects: 0
Study 1815115 — intervention group
Group type: COMPARATOR
Intervention: 2% methohexital solution
Number of subjects: 0
Study 1815115 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/kg methohexital
Number of subjects: 0
Study 6222545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate treatment
Number of subjects: 46
Study 6222545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy according to Hammerstein
Number of subjects: 46
Study 30995665 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromogranin A (CgA) measurement using NEOLISATM kit (EuroDiagnostica)
Number of subjects: 200
Study 30995665 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromogranin A (CgA) measurement
Number of subjects: 200
Study 30995665 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring CgA levels over 12 months
Number of subjects: 200
Study 30995665 — intervention group
Group type: COMPARATOR
Intervention: CgA levels in non-neoplastic diseases (COPD and IPF)
Number of subjects: 200
Study 30995665 — intervention group
Group type: COMPARATOR
Intervention: CgA levels in neoplastic diseases (NSCLC, SCC)
Number of subjects: 200
Study 30995665 — intervention group
Group type: COMPARATOR
Intervention: CgA levels in neuroendocrine SCLC
Number of subjects: 200
Study 29856472 — intervention group
Group type: EXPERIMENTAL
Intervention: TXYF granules
Number of subjects: 160
Study 29856472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 26708331 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Training Technique (ATT)
Number of subjects: 100
Study 26708331 — intervention group
Group type: COMPARATOR
Intervention: No-intervention condition
Number of subjects: 100
Study 24185114 — intervention group
Group type: EXPERIMENTAL
Intervention: NASHA hyaluronic acid
Number of subjects: 442
Study 24185114 — intervention group
Group type: COMPARATOR
Intervention: methylprednisolone acetate (MPA)
Number of subjects: 442
Study 22988687 — intervention group
Group type: EXPERIMENTAL
Intervention: Test paste (8% arginine and calcium carbonate)
Number of subjects: 66
Study 22988687 — intervention group
Group type: COMPARATOR
Intervention: Control paste (Nupro non-fluoridated pumice based prophylaxis paste)
Number of subjects: 66
Study 22988687 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Test and Control pastes
Number of subjects: 66
Study 20052358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (300,000 IU)
Number of subjects: 19
Study 20052358 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 17912104 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotène Oral Balance gel and toothpaste used daily
Number of subjects: 36
Study 17912104 — intervention group
Group type: COMPARATOR
Intervention: Carboxymethylcellulose gel and Oral-B toothpaste (control)
Number of subjects: 36
Study 16221568 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 18
Study 16221568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12196654 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) recordings
Number of subjects: 33
Study 10645799 — intervention group
Group type: EXPERIMENTAL
Intervention: PEM regimen (cisplatin 60 mg/m2 on day 1, etoposide 40 mg/m2 on days 1, 2, and 3, mitomycin-C 7 mg/m2 on day 1)
Number of subjects: 26
Study 10645799 — intervention group
Group type: EXPERIMENTAL
Intervention: Long CF regimen (cisplatin 8 mg/m2 on days 1-5, 8-12, 15-19, and 22-26, 5-fluorouracil 300 mg/m2 as a 24 h infusion or oral UFT-E 400 mg/m2 on days 1-28)
Number of subjects: 26
Study 8682929 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR) procedure with e‐PFTE membrane placement
Number of subjects: 11
Study 8682929 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment modality (control) without e‐PFTE membrane placement
Number of subjects: 11
Study 2269802 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures (Oucher and Analogue Chromatic Continuous Scale)
Number of subjects: 25
Study 2269802 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral measures (Children's Hospital of Eastern Ontario Pain Scale, CHEOPS)
Number of subjects: 25
Study 7438383 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1.0 g daily)
Number of subjects: 4524
Study 7438383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4524
Study 31364036 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 155
Study 31364036 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 155
Study 29251980 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated bar context condition
Number of subjects: 143
Study 29251980 — intervention group
Group type: COMPARATOR
Intervention: Neutral context condition
Number of subjects: 143
Study 29251980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (simulated bar and neutral)
Number of subjects: 143
Study 26153159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame lignans and vitamin E (SVE)
Number of subjects: 72
Study 26153159 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 72
Study 23522341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 0
Study 21460508 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily bathing with chlorhexidine gluconate (CHG) using CHG-impregnated cloths
Number of subjects: 14801
Study 21460508 — intervention group
Group type: COMPARATOR
Intervention: Daily bathing with soap and water
Number of subjects: 14801
Study 18656274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab bolus
Number of subjects: 1005
Study 18656274 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab bolus
Number of subjects: 1005